Olanzapine IM Dosing for Acute Agitation
For acute agitation, the recommended intramuscular (IM) olanzapine dose is 10 mg, with lower doses of 5-7.5 mg considered when clinical factors warrant; maximum daily dose is 30 mg with subsequent injections spaced at least 2 hours apart (minimum 4 hours after second dose). 1, 2
Standard Dosing Algorithm
Initial dose:
- Standard adult dose: 10 mg IM 1, 2
- Lower dose (5-7.5 mg IM) when clinical factors warrant 1, 2
- Efficacy demonstrated across 2.5-10 mg range 3, 4
Repeat dosing if agitation persists:
- Subsequent doses up to 10 mg may be given 1, 2
- Minimum interval: 2 hours after initial dose, 4 hours after second dose 1, 2
- Maximum daily dose: 30 mg (e.g., three 10 mg doses) 1, 2
- Assess for orthostatic hypotension before each subsequent dose 1, 2
Special Population Adjustments
Elderly patients:
Debilitated patients or those predisposed to hypotension:
Hepatic impairment:
Critical Safety Considerations
Maximal dosing risks:
- Three doses of 10 mg (2-4 hours apart) associated with substantial orthostatic hypotension 1, 2
- Do not administer additional dose if clinically significant postural blood pressure change occurs 1, 2
Benzodiazepine combination:
- CRITICAL WARNING: Fatalities reported with concurrent benzodiazepine use, especially high-dose olanzapine 5
- Risk of oversedation and respiratory depression 5
Route-specific warnings:
- IM ONLY - do not administer IV or subcutaneously per FDA labeling 1, 2
- Inject slowly, deep into muscle mass 1, 2
Reconstitution (IM Formulation)
- Use 2.1 mL Sterile Water for Injection only 1, 2
- Final concentration: approximately 5 mg/mL 1, 2
- Use immediately within 1 hour after reconstitution 1, 2
Injection volumes:
Drug Incompatibilities
Do NOT combine in syringe with:
- Diazepam (causes precipitation) 1, 2
- Lorazepam for reconstitution (delayed reconstitution time) 1, 2
- Haloperidol (low pH degrades olanzapine) 1, 2
Transition to Oral Therapy
When ongoing therapy indicated, initiate oral olanzapine 5-20 mg/day as soon as clinically appropriate 1, 2
Evidence Quality Notes
The FDA labeling 1, 2 provides the most authoritative dosing guidance, supported by randomized controlled trials demonstrating efficacy across the 2.5-10 mg dose range 3, 4. The ESMO guidelines 5 provide important context for special populations and safety warnings, particularly regarding benzodiazepine combinations. Recent geriatric emergency guidelines 6 emphasize using lowest effective doses and preferring oral formulations when possible, though this addresses a different population than acute agitation requiring parenteral therapy.
Important caveat: While IV olanzapine is used off-label in some centers 7, 8, 9, 10, it remains not FDA-approved and should not be considered standard practice without institutional protocols addressing this off-label use.